YIH
RNAM

Y-Intercept (HK)’s Avidity Biosciences RNAM Stock Holding History

Y-Intercept (HK)’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,041
Closed -$307K – 1929
2025
Q3 		$307K Buy
+7,041
New +$285K 0.01% 1374
2025
Q1 		– Sell
-13,281
Closed -$386K – 1546
2024
Q4 		$386K Buy
+13,281
New +$555K 0.03% 839
2022
Q4 		– Sell
-10,539
Closed -$172K – 1296
2022
Q3 		$172K Buy
+10,539
New +$202K 0.02% 840

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Y-Intercept (HK)'s RNAM Position: Q4 2025 in Review

Y-Intercept (HK) sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 7,041 shares — an estimated $307K sold.

Y-Intercept (HK) first reported a position in RNAM in Q3 2022 and held it in 3 quarters. The position peaked at $386K in Q4 2024. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Y-Intercept (HK) reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 7,041 Avidity Biosciences shares in Q4 2025, an estimated $307K.
  • Y-Intercept (HK) first reported a position in Avidity Biosciences in Q3 2022 and held it in 3 quarters.
  • Y-Intercept (HK)'s Avidity Biosciences position peaked at $386K in Q4 2024.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Y-Intercept (HK)'s 13F filing for Q4 2025, filed 13 Feb 2026.